Maze Therapeutics, Inc.
Metrics score locked — part of Premium
Price analysis
Chart shows the share price.
| Point in time | Price |
|---|---|
| Oct 31, 2025 | 28.5 EUR |
| Nov 7, 2025 | 24.7 EUR |
| Nov 14, 2025 | 27.9 EUR |
| Nov 21, 2025 | 31.5 EUR |
| Nov 28, 2025 | 32.6 EUR |
| Dec 5, 2025 | 35.8 EUR |
| Dec 12, 2025 | 33.1 EUR |
| Dec 19, 2025 | 35.6 EUR |
| Dec 26, 2025 | 35.7 EUR |
| Jan 2, 2026 | 33.9 EUR |
| Jan 9, 2026 | 34.6 EUR |
| Jan 16, 2026 | 35.1 EUR |
| Jan 23, 2026 | 37.7 EUR |
| Jan 30, 2026 | 36.6 EUR |
| Feb 6, 2026 | 38.2 EUR |
| Feb 13, 2026 | 38.8 EUR |
| Feb 20, 2026 | 37.6 EUR |
| Feb 27, 2026 | 38.6 EUR |
| Mar 6, 2026 | 38.8 EUR |
| Mar 13, 2026 | 43.8 EUR |
| Mar 20, 2026 | 41.6 EUR |
| Mar 27, 2026 | 26.4 EUR |
| Apr 3, 2026 | 24.9 EUR |
| Apr 10, 2026 | 22.8 EUR |
| Apr 17, 2026 | 23.8 EUR |
| Apr 24, 2026 | 22 EUR |
| May 1, 2026 | 23.2 EUR |
| May 8, 2026 | 22.1 EUR |
| May 15, 2026 | 22 EUR |
| May 22, 2026 | 22.2 EUR |
| May 29, 2026 | 22.7 EUR |
| Jun 5, 2026 | 20.9 EUR |
| Jun 12, 2026 | 20.8 EUR |
| Jun 19, 2026 | 22.4 EUR |
| Jun 26, 2026 | 24.9 EUR |
| Jul 3, 2026 | 27.3 EUR |
| Jul 10, 2026 | 26.7 EUR |
| Jul 17, 2026 | 24.6 EUR |
| Jul 24, 2026 | 24.3 EUR |
| Jul 31, 2026 | 23.4 EUR |
| Aug 7, 2026 | 24.8 EUR |
| Aug 14, 2026 | 23.5 EUR |
| Aug 21, 2026 | 25.2 EUR |
| Aug 28, 2026 | 23.6 EUR |
| Sep 4, 2026 | 22.6 EUR |
| Sep 11, 2026 | 21.2 EUR |
| Sep 18, 2026 | 19.7 EUR |
| Sep 25, 2026 | 22.8 EUR |
| Oct 2, 2026 | 23.5 EUR |
| Oct 9, 2026 | 24.2 EUR |
| Oct 16, 2026 | 24.5 EUR |
| Oct 23, 2026 | 27.7 EUR |
| Oct 26, 2026 | 27.8 EUR |
Price as of: Oct 26, 2026 closing price
Key metrics overview
Metrics score locked — part of Premium
Unlock metrics and scores View Premium
Valuation
- Price-to-Earnings Ratio
No meaningful value available - Price-to-Sales Ratio
Available with Premium - Price-to-Free-Cashflow
Available with Premium - Growth-Adjusted P/E
Available with Premium
Growth
- Revenue Growth
No meaningful value available - Earnings Growth
Available with Premium - Free Cash Flow Growth
Available with Premium - Net Margin Change
Available with Premium - Free Cash Flow Margin Change
Available with Premium - Earnings-per-Share Growth
Available with Premium - Growth Consistency
Available with Premium
Profitability
Return on Equity −37.35%- Return on Assets
Available with Premium - Return on Invested Capital
Available with Premium - Operating Profit Margin
Available with Premium - Net Profit Margin
Available with Premium
Stability
Revenue Stability 37 / 100- Earnings Stability
Available with Premium - Cashflow Stability
Available with Premium - Crisis Performance
Available with Premium - Price Fluctuations
Available with Premium - Maximum Price Loss
Available with Premium
Debt
- Debt-to-Equity Ratio
Available with Premium - Debt-to-Assets
Available with Premium - Net Debt / EBITDA
Available with Premium - Interest Coverage Ratio
Available with Premium
Cashflow
- Operating Cashflow
Available with Premium - Free Cashflow
Available with Premium - Free Cashflow Margin
Available with Premium
Dividends
- Dividend Yield
Available with Premium - Dividend Payout Ratio
Available with Premium - Dividend Growth
Available with Premium - Years without a cut
Available with Premium
Market comparison
The Fundamentals Score is higher than that of 38% of the other companies across the entire market and 48% of the other companies in the Biotech industry.
Revenue and Profit Performance
| Point in time | Revenue | Profit |
|---|---|---|
| FY25 (Dec 31, 2025) | 0 M USD | −131.1 M USD |
| FY24 (Dec 31, 2024) | 167.5 M USD | 52.2 M USD |
| FY23 (Dec 31, 2023) | 0 M USD | −100.4 M USD |
| FY22 (Dec 31, 2022) | 0 M USD | −114.9 M USD |
All amounts in millions USD
More Companies
The largest other companies in Biotech, part of the Healthcare sector.